专利号:US-9090925-B2 优先权日:2006-01-20 标 题:Synthesis of (6S)-5,6,7,8-tetrahydrofolic acid 发明人:JONES JR GERALD S; ST LAURENT JOSEPH P; GOODRICH SCOTT A; MAGUIRE GEORGE 权利人:JONES JR GERALD S; ST LAURENT JOSEPH P; GOODRICH SCOTT A; MAGUIRE GEORGE; CHEMIC LAB INC 摘要:A process for the large-scale chemoenzymatic production of (6S)-5-methyl-5,6,7,8-tetrahydrofolic acid, also known as (6S)-5-methylTHFA, the process comprising the steps of: (1) reducing folic acid (FA) so as to yield dihydrofolic acid (DHFA); (2) stereoselectively reducing DHFA with dihydrofolate reductase (DHFR) in the presence of NADP/NADPH, glucose and GluDH so as to yield (6S)-THFA; (3) converting (6S)-THFA to (6S)-5-methlTHFA; and (4) isolating (6S)-5-methylTHFA.
专利号:US-2009191610-A1 优先权日:2005-08-18 标 题 :Microorganisms With Increased Efficiency for Methionine Synthesis 发明人:ZELDER OSKAR; HEROLD ANDREA; KLOPPROGGE CORINNA; SCHRODER HARTWIG; HAEFNER STEFAN; HEINZLE ELMAR; WITTMANN CHRISTOPH; KROEMER JENS; PERO JANICE G; YOCUM R ROGERS; PATTERSON THOMAS A; WILLIAMS MARK; HERMAN THERON 权利人:EVONIK DEGUSSA GMBH 摘要:The present invention relates to methods for the production of microorganisms with increased efficiency for methionine synthesis, microorganisms with increased efficiency for methionine synthesis, and methods for determining the optimal metabolic flux for organisms with respect to methionine synthesis.
专利号:US-9885064-B2 优先权日:2008-01-22 标 题 :Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol 发明人:BURK MARK J; SCHILLING CHRISTOPHE H; BURGARD ANTHONY P; TRAWICK JOHN D 权利人:GENOMATICA INC 摘要:The invention provides a non-naturally occurring microbial organism having an acetyl-CoA pathway and the capability of utilizing syngas or syngas and methanol. In one embodiment, the invention provides a non-naturally occurring microorganism, comprising one or more exogenous proteins conferring to the microorganism a pathway to convert CO, CO 2 and/or H 2 to acetyl-coenzyme A (acetyl-CoA), methyl tetrahydrofolate (methyl-THF) or other desired products, wherein the microorganism lacks the ability to convert CO or CO 2 and H 2 to acetyl-CoA or methyl-THF in the absence of the one or more exogenous proteins. For example, the microbial organism can contain at least one exogenous nucleic acid encoding an enzyme or protein in an acetyl-CoA pathway. The microbial organism is capable of utilizing synthesis gases comprising CO, CO 2 and/or H 2 , alone or in combination with methanol, to produce acetyl-CoA. The invention additionally provides a method for producing acetyl-CoA, for example, by culturing an acetyl-CoA producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an acetyl-CoA pathway enzyme or protein in a sufficient amount to produce acetyl-CoA, under conditions and for a sufficient period of time to produce acetyl-CoA.
专利号:EP-1645276-A1 优先权日:2004-10-08 标题:Treatment of neurodegenerative disorders 发明人:DURGA JANE; VERHOEF PETRA 权利人:WAGENINGEN CT FOR FOOD SCIENCE 摘要:The present invention is dedicated to the treatment of neurodegenerative disorders, in particular age related cognitive decline and age related hearing loss. These disorders can be alleviated by increasing 10-formyltetrahydrofolate or increasing thymidylate synthesis. The invention is of particular benefit to subjects that are MTHFR 677CT heterozygote and MTHFR 677CC homozygote. n The substance that increases 10-formyltetrahydrofolate or increases thymidylate synthesis is selected from 10-formyltetrahydrofolate, 5-formyltetrahydrofolate, 5,10-methenyltetrahydrofolate, 5,10-methylentetrahydrofolate, methionine, S-adenosylmethionine and poly-glutamate forms of 10-formyltetrahydrofolate, 5-formyltetrahydrofolate, 5,10-methenyltetrahydrofolate and 5,10-methylentetrahydrofolate and the substance may be in an acid or salt or ester form.
专利号:US-2015317458-A1 优先权日:2012-12-06 标 题 :In silico prediction of enhanced nutrient content in plants by metabolic modelling 发明人:LOTZ KATRIN; LEPS MICHAEL; LEMKE RAINER; JUNKER BJOERN; SCHREIBER FALK 权利人:BASF PLANT SCIENCE CO GMBH 摘要:The present invention relates to a method for identifying at least one metabolic conversion step, the modulation of which increases the amount of a metabolite of interest in a plant cell, plant or plant part, said method comprising establishing a stoichiometric network model for the metabolism of the plant cell, plant or plant part including the synthesis pathway for the metabolite of interest, identifying at least one candidate metabolic conversion step by applying at least one algorithm of Growth-coupled Design, and validating the at least one candidate metabolic conversion step by a constraint-based modeling approach in the stoichiometric network model, wherein an increase in the metabolite of interest occurring in said constraint-based modeling approach is indicative for a metabolic conversion step, the modulation of which increases the amount of the metabolite of interest in the plant cell, plant or plant part. The present invention further relates to a method for generating a plant cell, plant or plant part which produces an increased amount of a metabolite of interest when compared to a control, said method comprising identifying a metabolic conversion step, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, by the method for identifying a metabolic conversion step and modulating the said metabolic conversion step such that the amount of the metabolite of interest is increased in vivo in a plant cell, plant or plant part.
专利号:US-2024318209-A1 优先权日:2023-09-14 标 题 :Genetically engineered bacterium using glucose as substrate for de novo synthesis of vanillin and application thereof
1: Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. eCollection 2016 Jul. 2: Wettergren Y, Taflin H, Odin E, Kodeda K, Derwinger K. A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. Cancer Chemother Pharmacol. 2015 Jan;75(1):37-47. doi: 10.1007/s00280-014-2611-9. Epub 2014 Oct 24. 3: Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS. Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care. 2014 Mar 1;20(3):e90-7. doi: 10.1007/s10637-013-0056-3. Epub 2013 Dec 15.
合成参考文献
参考文献:10.1016/j.mito.2011.06.009 摘要:Tondo M, Málaga I, O'Callaghan M, Serrano M, Emperador S, Ormazabal A, Ruiz-Pesini E, Montoya J, Garcia-Silva MT, Martin-Hernandez E, Garcia-Cazorla A, Pineda M, Artuch R. Biochemical parameters to assess choroid plexus dysfunction in Kearns-Sayre syndrome patients. Mitochondrion. 2011 Nov;11(6):867–70. doi: 10.1016/j.mito.2011.06.009. 参考文献:10.3164/jcbn.10-129 摘要:Chung HK, Kim OY, Lee H, Do HJ, Kim YS, Oh J, Kang SM, Shin MJ. Relationship between dietary folate intake and plasma monocyte chemoattractant protein-1 and interleukin-8 in heart failure patients. J Clin Biochem Nutr. 2011 Jul;49(1):62–6. 参考文献:10.1007/s00335-011-9351-5 摘要:Pickell L, Wu Q, Wang XL, Leclerc D, Friedman H, Peterson AC, Rozen R. Targeted insertion of two Mthfr promoters in mice reveals temporal- and tissue-specific regulation. Mamm Genome. 2011 Dec;22(11-12):635–47. doi: 10.1007/s00335-011-9351-5. 参考文献:10.1021/jf201120n 摘要:Wang C, Riedl KM, Somerville J, Balasubramaniam VM, Schwartz SJ. Influence of high-pressure processing on the profile of polyglutamyl 5-methyltetrahydrofolate in selected vegetables. J Agric Food Chem. 2011 Aug 24;59(16):8709–17. 参考文献:10.1016/j.braindev.2011.05.014 摘要:Prasad AN, Rupar CA, Prasad C. Methylenetetrahydrofolate reductase (MTHFR) deficiency and infantile epilepsy. Brain Dev. 2011 Oct;33(9):758–69. doi: 10.1016/j.braindev.2011.05.014.